John Overdeck’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $565M | Sell |
1,875,937
-116,640
| -6% | -$35.2M | 0.41% | 37 |
|
|
2026
Q1 | $659M | Buy |
1,992,577
+1,376,457
| +223% | +$468M | 0.53% | 20 |
|
|
2025
Q4 | $245M | Buy |
616,120
+20,194
| +3% | +$8.94M | 0.35% | 31 |
|
|
2025
Q3 | $272M | Buy |
595,926
+252,621
| +74% | +$103M | 0.4% | 12 |
|
|
2025
Q2 | $112M | Buy |
343,305
+145,890
| +74% | +$40.4M | 0.2% | 128 |
|
|
2025
Q1 | $53.3M | Buy |
197,415
+90,298
| +84% | +$23.2M | 0.11% | 212 |
|
|
2024
Q4 | $25.2M | Buy |
107,117
+87,969
| +459% | +$23.1M | 0.06% | 414 |
|
|
2024
Q3 | $5.27M | Sell |
19,148
-83,770
| -81% | -$21.8M | 0.01% | 1060 |
|
|
2024
Q2 | $25M | Buy |
102,918
+406
| +0.4% | +$64.1K | 0.06% | 385 |
|
|
2024
Q1 | $15.3M | Buy |
+102,512
| New | +$17.1M | 0.04% | 522 |
|
|
2023
Q4 | – | Sell |
-3,300
| Closed | -$584K | – | 3124 |
|
|
2023
Q3 | $584K | Sell |
3,300
-221,369
| -99% | -$42.2M | ﹤0.01% | 2215 |
|
|
2023
Q2 | $42.7M | Buy |
224,669
+57,323
| +34% | +$11.4M | 0.11% | 246 |
|
|
2023
Q1 | $33.5M | Sell |
167,346
-15,361
| -8% | -$3.23M | 0.1% | 249 |
|
|
2022
Q4 | $43.4M | Sell |
182,707
-34,005
| -16% | -$7.25M | 0.14% | 176 |
|
|
2022
Q3 | $43.4M | Buy |
+216,712
| New | +$41.3M | 0.15% | 173 |
|
|
2022
Q2 | – | Sell |
-73,949
| Closed | -$12.1M | – | 2471 |
|
|
2022
Q1 | $12.1M | Buy |
+73,949
| New | +$11.3M | 0.04% | 547 |
|
|
2021
Q2 | – | Sell |
-36,619
| Closed | -$5.17M | – | 3992 |
|
|
2021
Q1 | $5.17M | Buy |
+36,619
| New | +$5.51M | 0.01% | 1026 |
|
|
2018
Q4 | – | Sell |
-20,675
| Closed | -$1.81M | – | 2942 |
|
|
2018
Q3 | $1.81M | Sell |
20,675
-102,708
| -83% | -$10.3M | ﹤0.01% | 1550 |
|
|
2018
Q2 | $12.2M | Sell |
123,383
-132,993
| -52% | -$13.2M | 0.04% | 587 |
|
|
2018
Q1 | $30.5M | Sell |
256,376
-46,000
| -15% | -$5.93M | 0.1% | 251 |
|
|
2017
Q4 | $38.4M | Buy |
302,376
+158,502
| +110% | +$19.9M | 0.13% | 211 |
|
|
2017
Q3 | $16.9M | Buy |
143,874
+141,127
| +5,137% | +$12M | 0.06% | 364 |
|
|
2017
Q2 | $219K | Buy |
+2,747
| New | +$176K | ﹤0.01% | 2769 |
|
|
2016
Q2 | – | Sell |
-84,077
| Closed | -$5.28M | – | 2878 |
|
|
2016
Q1 | $5.28M | Buy |
+84,077
| New | +$5.59M | 0.03% | 678 |
|
|
2015
Q3 | – | Sell |
-18,630
| Closed | -$2.23M | – | 2158 |
|
|
2015
Q2 | $2.23M | Buy |
+18,630
| New | +$2.23M | 0.01% | 1134 |
|
|
2013
Q3 | – | Sell |
-16,190
| Closed | -$502K | – | 1814 |
|
|
2013
Q2 | $502K | Buy |
+16,190
| New | +$431K | ﹤0.01% | 1406 |
|
Other funds holding ALNY
John Overdeck's ALNY Position: Q2 2026 in Review
John Overdeck reduced its Alnylam Pharmaceuticals (ALNY) stake by 5.9% in Q2 2026, selling an estimated $35.2M and leaving 1,875,937 shares worth $565M. The position accounts for 0.41% of the portfolio, ranked #37.
John Overdeck first reported a position in ALNY in Q2 2013 and has held it in 26 quarters since. The position peaked at $659M in Q1 2026. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- John Overdeck held 1,875,937 shares of Alnylam Pharmaceuticals worth $565M as of Q2 2026.
- John Overdeck sold 116,640 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $35.2M.
- Alnylam Pharmaceuticals made up 0.41% of John Overdeck's portfolio in Q2 2026, its #37 holding.
- John Overdeck first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
- John Overdeck's Alnylam Pharmaceuticals position peaked at $659M in Q1 2026.
- 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.